Organ on chip Market Size

Organ on chip Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The market for organs-on-chips is expected to grow at a fast rate, and will be worth $ 230 million in 2024, and will stay at the same level in 2032. With a CAGR of 11.7 percent from 2023 to 2032, this shows that the market is very dynamic, driven by technological progress and the increasing demand for novel drug development and testing solutions. The market growth is driven by the need for more efficient and humane alternatives to animal testing, as well as the growing need for individualized medicine and individualized therapies. In addition, the market is pushed forward by advances in microfluidics, biomaterials and 3D cell culture technology, which enhances the functionality and accuracy of organ-on-chip systems. The leading companies are Emulate and Mimetas, which are at the forefront of innovation and actively participate in strategic collaborations to expand their product offerings and research capabilities. Emulate, for example, has established strategic relationships with major pharmaceutical companies to integrate organ-on-chip technology into the development process and speed up the development of new drugs. These strategic initiatives will be crucial to the future of the organ-on-chip market as the industry evolves.

Regional Market Size

Regional Deep Dive

In the market for organs on a chip, which is experiencing significant growth in all regions of the world, the most important growth factors are the rapid development of biotechnology, the increasing demand for individualized medicine, and the trend towards more ethical testing methods. The regional market is characterized by its own special characteristics, which are determined by local legislation, research and development capabilities, and market needs. North America is leading in innovation and investment, Europe is focusing on regulation and cooperation, and Asia-Pacific is rapidly developing its research capabilities. The Middle East and Africa are developing rapidly and are a promising market. Latin America is beginning to explore the potential of organs on a chip for drug development and disease modeling.

North America

• The National Institutes of Health has launched a campaign to promote the organ-on-a-chip technology, offering to finance research projects that could improve drug testing and disease modeling.
• In the field of organ-on-chip, Emulate, Inc. and TissUse are at the forefront. Recent collaborations are aimed at integrating these platforms into pharmaceutical research.
• This organ-on-a-chip technology is increasingly gaining the attention of the regulatory authorities, such as the FDA. This could lead to a faster approval process for new drugs and therapies.

Europe

• A number of projects have been funded under Horizon 2020, a European Union programme promoting research collaboration between universities and industry.
• The European Medicines Agency is currently working on guidelines for the integration of data from organ-on-chips into regulatory submissions. This could significantly speed up the approval of new drugs.
• In countries such as Germany and Great Britain, biotechnological research is being supported by universities and research institutions, and a variety of organ-on-a-chip models are being developed for various purposes.

Asia-Pacific

• The Chinese organ-on-a-chip research has been developing rapidly, and the Tsinghua University has been leading the research, which aims to create a more accurate disease model for drug testing.
• In Japan, the government has started to develop this technology, which has the potential to replace animal experiments and increase the effectiveness of drugs.
• South Korea is now launching new organ-on-chip companies with a focus on regenerative medicine and applications in personalized medicine.

MEA

• It is not only in the United Arab Emirates that the development of biotechnology is taking place, but also in other countries. In the United Arab Emirates, for example, there are several laboratories for the development of the organ-on-a-chip, which are intended to improve the quality of health care in the country.
• Using this approach, the development of new applications for the so-called organ-on-a-chip, especially for the discovery of drugs and the testing of toxicology, is being pushed forward by collaborations between the universities and the international biotech industry.
• In Israel, the regulatory framework is evolving to accommodate new biotechnologies, which might make it easier for clinical research to adopt organ-on-a-chip devices.

Latin America

• Brazil has begun to experiment with the organ-on-a-chip. Some universities are working on the use of such systems in the development of new drugs and the modelling of diseases.
• The Argentine academic and biotechnological environment is beginning to develop a common strategy to address the local health problems.
• In the meantime, the authorities in the region are beginning to recognize the importance of new testing methods. This may well lead to an increase in support for the development of organ-on-a-chip research.

Did You Know?

“Moreover, the organ-on-a-chip can reproduce the physiological responses of human organs, reducing the need for animal experiments by as much as ninety per cent.” — National Institutes of Health (NIH)

Segmental Market Size

The market for organs-on-a-chip plays a key role in the broader biotechnology and pharmaceutical industries, which are currently experiencing a period of robust growth. This is driven by a rising demand for more efficient drug screening methods, the need for individualized medicine, and stricter regulatory requirements for preclinical testing. While the use of animals is under increasing ethical scrutiny, organs-on-chips offer a viable alternative to the current testing methods.

It is in the implementation stage that the organ-on-a-chip is now being used. The companies Emulate and Mimetas are leading the way. These companies are deploying their platforms in a number of research settings, mainly in North America and Europe, where the regulatory framework is more favourable. In particular, the main applications are in drug discovery, toxicology and disease modelling, with the most notable applications being in oncology and in the field of the heart. The current interest in deploying this technology is largely due to the drive for sustainable drug discovery and the impact of the COVID-19 pandemic. However, the developments in microfluidics and biomaterials are still to come and continue to shape the evolution of the technology.

Future Outlook

Consequently, the organ-on-a-chip market is expected to show a CAGR of 11.7 percent between 2024 and 2032. The trend towards higher growth is due to the growing demand for drug screening and the growing demand for a more ethical and more efficient alternative to animal testing. The market is expected to reach about a billion dollars in 2032, reflecting the steady acceptance of organ-on-a-chip technology in various industries, such as pharmaceuticals, biotechnology and academic research.

The development of microfluidics and 3D bioprinting will enhance the functionality and applicability of organ-on-a-chip devices. The more accurate modelling of human physiology that these innovations will enable will enable a better assessment of drug efficacy and safety. Furthermore, a more supportive regulatory environment and the increased funding of research and development in this field will facilitate the penetration of this technology into the market. Consequently, it is anticipated that by 2032 organ-on-a-chip devices will be used in more than a third of all preclinical drug development processes, which will further highlight their importance in the biomedical field.

The organ-on-a-chip market will be shaped by the growing trend of personal medicine, the rising cost and time pressures of drug development, and the growing focus on reducing the risk of clinical trials. The demand for new, more accurate models of human organs will increase. The organ-on-a-chip market players must be flexible and respond to these trends to seize the opportunities ahead.